Why the Admedus Ltd share price is 14% higher today


Whilst the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) may have started the day relatively flat, it certainly wasn’t the case for Admedus Ltd (ASX: AHZ). The share price of the biotech company rocketed higher at the open and is currently up by over 14% at present.

The jump in its share price comes following the release of its fourth quarter report which showed a 40% increase in full year sales to $14.1 million. Furthermore, its full year forecast of sales growth of at least 50% in FY 2017 has no doubt gone down well with investors.

This growth is largely the result of its Infusion business being awarded a 5-year contract with the new Royal Adelaide Hospital for the installation of the arcomed Chroma Infusion pump system. It expects this contract to have a material impact on annual revenue starting in the first quarter of FY 2017.

Chairman and interim CEO Wayne Paterson anticipates its CardioCel product to also continue growing sales on a quarter on quarter basis. Although sales of the regenerative heart patch may have underwhelmed thus far, the company expects it to play a part in helping the company achieve profitability in FY 2018.

For the quarter the company reported a net cash loss of $4.4 million. This left it with a cash balance of $8.8 million and $3.5 million in research and development rebates expected in FY 2017. Thankfully for shareholders cost cutting is expected to reduce operating costs by $12 million during FY 2017, which should hopefully mean the company doesn’t have to initiate any capital raising in the next 12 months.

Whilst I think there are positives to be found in an investment in Admedus, in the sector I personally have a preference for Pro Medicus Limited (ASX: PME) and REVA Medical Inc (ASX: RVA). Both companies are well worth researching further in my opinion.

If you do wish to add any of these shares to your portfolio I would highly recommend swapping them in for one of these three rotten shares if you own them. Each could be harming your portfolio and may be better off taken out if you ask me.

3 Rotten Shares to Sell, and 1 to Buy Today

After a double-digit rally for the ASX since 2016 lows, investors should be on high alert. You'll find a full rundown below of 3 shares we think you should avoid today plus one top pick worth buying, even if the market turns south and the RBA keeps rates at an "emergency low." Simply click here to uncover these stocks.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.